外泌体在心力衰竭发生发展中的作用及临床价值

doi:10.3969/j.issn.1004-583X.2024.03.011

摘要/Abstract

摘要：

心力衰竭(heart failure,HF)是各种心血管疾病的终末阶段,具有较高的发病率以及致死率。外泌体可以通过影响肾素-血管紧张素系统、心肌纤维化、心肌细胞凋亡、新生血管生成等多方面参与HF的发生与发展。外泌体不但可以作为HF的诊断标志物,而且能够作为靶向药物递送或干细胞治疗的载体助力于HF的治疗。本文就外泌体在HF发生发展中的作用、诊断以及治疗研究进展进行综述。

关键词: 外泌体, 心力衰竭, 机制, 诊断, 治疗

中图分类号:

R329.24

孙庆, 王海龙, 米庆, 乐暾, 牟华明. 外泌体在心力衰竭发生发展中的作用及临床价值[J]. 临床荟萃, 2024, 39(3): 259-263.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2024.03.011

https://lchc.magtechjournal.com/CN/Y2024/V39/I3/259

图/表 2

参考文献 40

[1]	Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: A report of the heart failure society of america, heart failure association of the european society of cardiology, japanese heart failure society and writing committee of the universal definition of heart failure[J]. J Card Fail, 2021, Mar1:S1071- 9164(21)00050-6. Online ahead of print
[2]	《中国心血管健康与疾病报告》编写组. 《中国心血管健康与疾病报告2021》概述[J]. 中国心血管病研究, 2022, 20(7): 577-596.
[3]	Li H, Gu J, Sun X, et al. Isolation of swine bone marrow lin-/CD45-/CD133+ cells and cardio-protective effects of its exosomes[J]. Stem Cell Rev Rep, 2023, 19(1): 213-229.
[4]	Luo Z, Hu X, Wu C, et al. Plasma exosomes generated by ischaemic preconditioning are cardioprotective in a rat heart failure model[J]. Br J Anaesth, 2023, 130(1): 29-38.
[5]	Femminò S, Penna C, Margarita S, et al. Extracellular vesicles and cardiovascular system: Biomarkers and cardioprotective effectors[J]. Vascul Pharmacol, 2020, 135:106790.
[6]	Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367(6478):eaau6977.
[7]	Yao J, Huang K, Zhu D, et al. A minimally invasive exosome spray repairs heart after myocardial infarction[J]. ACS Nano, 2021, 15(7): 11099-11111. doi: 10.1021/acsnano.1c00628 pmid: 34152126
[8]	Lyu L, Wang H, Li B, et al. A critical role of cardiac fibroblast-derived exosomes in activating renin angiotensin system in cardiomyocytes[J]. J Mol Cell Cardiol, 2015, 89(Pt B): 268-279. doi: 10.1016/j.yjmcc.2015.10.022 pmid: 26497614
[9]	Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy[J]. J Clin Invest, 2014, 124(5): 2136-2146. doi: 10.1172/JCI70577 pmid: 24743145
[10]	Xiao M, Zeng W, Wang J, et al. Exosomes protect against acute myocardial infarction in rats by regulating the renin-angiotensin system[J]. Stem Cells Dev, 2021, 30(12): 622-631.
[11]	Moita MR, Silva MM, Diniz C, et al. Transcriptome and proteome profiling of activated cardiac fibroblasts supports target prioritization in cardiac fibrosis[J]. Front Cardiovasc Med, 2022, 9:1015473.
[12]	何亚州. 温中益气方对来源于外泌体的miR-320a调控PIK3CA防治慢性心力衰竭心肌纤维化的研究[D]. 南宁: 广西中医药大学, 2019.
[13]	Li J, Salvador AM, Li G, et al. Mir-30d regulates cardiac remodeling by intracellular and paracrine signaling[J]. Circ Res, 2021, 128(1): e1-e23.
[14]	Vaskova E, Ikeda G, Tada Y, et al. Sacubitril/valsartan improves cardiac function and decreases myocardial fibrosis via downregulation of exosomal mir-181a in a rodent chronic myocardial infarction model[J]. J Am Heart Assoc, 2020, 9(13): e015640.
[15]	Luther KM, Haar L, McGuinness M, et al. Exosomal miR-21a-5p mediates cardioprotection by mesenchymal stem cells[J]. J Mol Cell Cardiol, 2018, 119:125-137. doi: S0022-2828(18)30140-8 pmid: 29698635
[16]	Gao L, Qiu F, Cao H, et al. Therapeutic delivery of microRNA-125a-5p oligonucleotides improves recovery from myocardial ischemia/reperfusion injury in mice and swine[J]. Theranostics, 2023, 13(2): 685-703. doi: 10.7150/thno.73568 pmid: 36632217
[17]	Hou Z, Qin X, Hu Y, et al. Longterm exercise-derived exosomal miR-342-5p: A novel exerkine for cardioprotection[J]. Circ Res, 2019, 124(9): 1386-1400. doi: 10.1161/CIRCRESAHA.118.314635 pmid: 30879399
[18]	Sun C, Li W, Li Y, et al. MiR-182-5p mediated by exosomes derived from bone marrow mesenchymal stem cell attenuates inflammatory responses by targeting tlr4 in a mouse model of myocardial infraction[J]. Immune Netw, 2022, 22(6): e49.
[19]	Hu C, Liao J, Huang R, et al. MicroRNA-155-5p in serum derived-exosomes promotes ischaemia-reperfusion injury by reducing CypD ubiquitination by NEDD4[J]. ESC Heart Fail, 2023, 10(2):1144-1157. doi: 10.1002/ehf2.14279 pmid: 36631006
[20]	Ranjan P, Kumari R, Goswami SK, et al. Myofibroblast-derived exosome induce cardiac endothelial cell dysfunction[J]. Front Cardiovasc Med, 2021, 8:676267.
[21]	Qiao L, Hu S, Liu S, et al. MicroRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential[J]. J Clin Invest, 2019, 129(6): 2237-2250. doi: 10.1172/JCI123135 pmid: 31033484
[22]	Liu H, Zhang Y, Yuan J, et al. Dendritic cell-derived exosomal miR-494-3p promotes angiogenesis following myocardial infarction[J]. Int J Mol Med, 2021, 47(1): 315-325.
[23]	李光召. 肥厚心肌细胞来源外泌体miR-29a调控内皮细胞血管新生机制的研究[D]. 珠海: 遵义医科大学, 2020.
[24]	Liu S, Chen J, Shi J, et al. M1-like macrophage-derived exosomes suppress angiogenesis and exacerbate cardiac dysfunction in a myocardial infarction microenvironment[J]. Basic Res Cardiol, 2020, 115(2): 22.
[25]	Wu T, Chen Y, Du Y, et al. Circulating exosomal miR-92b-5p is a promising diagnostic biomarker of heart failure with reduced ejection fraction patients hospitalized for acute heart failure[J]. J Thorac Dis, 2018, 10(11): 6211-6220. doi: 10.21037/jtd.2018.10.52 pmid: 30622793
[26]	Wang L, Liu J, Xu B, et al. Reduced exosome miR-425 and miR-744 in the plasma represents the progression of fibrosis and heart failure[J]. Kaohsiung J Med Sci, 2018, 34(11): 626-633.
[27]	Lu W, Liu X, Zhao L, et al. MiR-22-3p in exosomes increases the risk of heart failure after down-regulation of FURIN[J]. Chem Biol Drug Des, 2023, 101(3):550-567.
[28]	Xie Y, Hang JZ, Zhang N, et al. Clinical significance of MiR-27a expression in serum exosomes in patients with heart failure[J]. Cell Mol Biol (Noisy-le-grand), 2022, 67(5): 324-331. doi: 10.14715/cmb/2021.67.5.44 pmid: 35818236
[29]	赵娟, 刘婷, 魏红, 等. 血浆外泌体微小RNA-206和N末端B型脑钠肽前体及同型半胱氨酸在心力衰竭患者中的表达水平及应用价值[J]. 中国医药, 2022, 17(9): 1326-1330.
[30]	孙晓燕, 亓良森, 赵海鸿, 等. 血清外泌体miR-122及miR-194在心肌梗死患者中诊断早期心衰的价值[J]. 解放军医学院学报, 2021, 42(9): 940-945.
[31]	Matsumoto S, Sakata Y, Suna S, et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction[J]. Circ Res, 2013, 113(3): 322-326. doi: 10.1161/CIRCRESAHA.113.301209 pmid: 23743335
[32]	Mentkowski KI, Lang JK. Exosomes engineered to express a cardiomyocyte binding peptide demonstrate improved cardiac retention in vivo[J]. Sci Rep, 2019, 9(1): 10041.
[33]	Yan F, Cui W, Chen Z. Mesenchymal stem cell-derived exosome-loaded microRNA-129-5p inhibits TRAF3 expression to alleviate apoptosis and oxidative stress in heart failure[J]. Cardiovasc Toxicol, 2022, 22(7): 631-645. doi: 10.1007/s12012-022-09743-9 pmid: 35546649
[34]	Xiong Y, Tang R, Xu J, et al. Tongxinluo-pretreated mesenchymal stem cells facilitate cardiac repair via exosomal transfer of miR-146a-5p targeting IRAK1/NF-κB p65 pathway[J]. Stem Cell Res Ther, 2022, 13(1): 289.
[35]	Gao L, Wang L, Wei Y, et al. Exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in swine[J]. Sci Transl Med, 2020, 12(561):eaay1318.
[36]	Davidson SM, Riquelme JA, Zheng Y, et al. Endothelial cells release cardioprotective exosomes that may contribute to ischaemic preconditioning[J]. Sci Rep, 2018, 8(1): 15885.
[37]	Li Q, Huang Z, Wang Q, et al. Targeted immunomodulation therapy for cardiac repair by platelet membrane engineering extracellular vesicles via hitching peripheral monocytes[J]. Biomaterials, 2022, 284:121529.
[38]	Cheng G, Zhu D, Huang K, et al. Minimally invasive delivery of a hydrogel-based exosome patch to prevent heart failure[J]. J Mol Cell Cardiol, 2022, 169:113-121. doi: 10.1016/j.yjmcc.2022.04.020 pmid: 35523270
[39]	Poupardin R, Wolf M, Strunk D. Adherence to minimal experimental requirements for defining extracellular vesicles and their functions[J]. Adv Drug Deliv Rev, 2021, 176:113872.
[40]	Kim JY, Rhim WK, Yoo YI, et al. Defined MSC exosome with high yield and purity to improve regenerative activity[J]. J Tissue Eng, 2021, 12:20417314211008626.

外泌体在心力衰竭发生发展中的作用及临床价值

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 40

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵世亮, 牛艳国, 赵燕民, 李俊青, 洪丽, 王献. 颅内动脉瘤介入术后认知功能障碍的因素探讨:基于PSM法[J]. 临床荟萃, 2025, 40(4): 320-324.
[2]	苏淼, 王飒爽, 赵东强. 《中国肥胖症消化内镜治疗专家共识》解读[J]. 临床荟萃, 2025, 40(4): 366-371.
[3]	蒲武涛, 肖宜欣, 妥丽, 凯丽比努尔·马木提, 范雪婷, 崇乐. 超声造影诊断肝包虫病的系统评价和meta分析[J]. 临床荟萃, 2025, 40(3): 197-204.
[4]	黄兴舟, 郑卫华, 张树桐, 陈燕浩. 载药微球与常规支气管动脉化疗栓塞术治疗晚期非小细胞肺癌的临床疗效及安全性对比[J]. 临床荟萃, 2025, 40(3): 243-250.
[5]	李忠标, 赵习浩, 杜敏, 王江, 于跃, 张佃良. 肠腔内生性卵巢外腹膜浆液性乳头状腺癌1例并文献复习[J]. 临床荟萃, 2025, 40(3): 257-261.
[6]	季万里, 马周, 石郁喜, 孙为生. 青年脊髓硬脊膜动静脉瘘1例并文献复习[J]. 临床荟萃, 2025, 40(3): 262-265.
[7]	陈诚, 钱卓宇, 全栩毅, 段圣武. 结直肠癌浆膜及肌层受累影像诊断的研究进展[J]. 临床荟萃, 2025, 40(3): 281-284.
[8]	叶倩, 刘申香. D-二聚体与接受PD-1/PD-L1抑制剂治疗的晚期肿瘤患者长期预后的关系:一项Meta分析[J]. 临床荟萃, 2025, 40(2): 101-106.
[9]	吴万锋, 王云云, 杨道坤. 新型冠状病毒感染应用不同抗病毒药物治疗后的疗效分析[J]. 临床荟萃, 2025, 40(2): 147-152.
[10]	崔凯歌, 刘丽莹, 孙利强, 胡婧, 于佳琪, 贾娟, 杨冀萍. 卵圆孔未闭:基于影像学证据的相关中枢神经机制[J]. 临床荟萃, 2025, 40(2): 172-179.
[11]	申帅洁, 陈荣梯, 朱嵩, 平芬. 乳酸脱氢酶在难治性肺炎支原体肺炎中的临床应用进展[J]. 临床荟萃, 2025, 40(2): 185-188.
[12]	字颖, 施雨辰, 施荣杰. 淋巴管平滑肌瘤病研究进展[J]. 临床荟萃, 2025, 40(2): 189-192.
[13]	周智明, 茹意, 李萍, 平芬. 多光谱照射联合常规治疗在慢性阻塞性肺疾病急性加重期患者中的临床应用[J]. 临床荟萃, 2025, 40(1): 27-32.
[14]	张迎秋, 张津, 葛世豪, 陈俊敏. 成人DWI脑皮质“花边征”1例并文献复习[J]. 临床荟萃, 2024, 39(9): 821-824.
[15]	散丹, 甄瑾. 脊髓硬脊膜动静脉瘘1例并文献复习[J]. 临床荟萃, 2024, 39(9): 825-827.